Free press releases distribution network?

Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Smoking Cessation Drugs Market to Reach $2.4 Billion in 2012 Predicts Visiongain Report - A new report by visiongain predicts that the world market for smoking cessation medicines will reach $2.4 billion for 2012 - Visiongain.com
Smoking Cessation Drugs Market to Reach $2.4 Billion in 2012 Predicts Visiongain Report

 

PRZOOM - /newswire/ - London, United Kingdom, 2012/04/16 - A new report by visiongain predicts that the world market for smoking cessation medicines will reach $2.4 billion for 2012 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

That revenue forecast appears in Smoking Cessation Drugs: World Market Prospects 2012-2022, published in April 2012. Visiongain is a business information provider based in London, UK.

Visiongain’s study predicts that the smoking cessation drug market will grow during the forecast period 2012 to 2022. Rising incidence and prevalence of smoking will stimulate revenue growth, especially in developing countries. The scope of the market is broadening, with millions of smokers wanting to stop smoking.

From 2012 to 2022, the pharmaceutical industry will improve treatments to stop smoking. The R&D pipeline is promising. New formulations and generics will be important too. Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market.

Kritika Chaudhari, a pharmaceutical industry analyst at visiongain, said: “In general, smoking cessation drugs suffer from two drawbacks at present. First, they have notable side effects. Second, is the challenge of smokers relapsing after treatment with anti-smoking medication. These difficulties are being recognised; addressing them will benefit the smoking cessation drugs market from 2012 to 2022.”

Visiongain’s report provides revenue forecasts to 2022 at world market, submarket, product and national level. It forecasts world sales for the following submarkets:

• Over-the-counter (OTC) smoking cessation products;
• Prescription (Rx) drugs;
• Nicotine replacement therapy (NRT);
• Nicotine receptor partial agonists;
• Antidepressant therapy segment.

That investigation forecasts sales of leading drugs in the smoking treatments market, including Nicorette, Nicotinell and Champix/Chantix. Research, data and analyses cover activities of Pfizer, GSK, Novartis and other pharmaceutical companies.

The analysis includes researching the R&D pipeline, interviewing authorities on the industry and forecasting revenues in leading national markets. Countries analysed are the US, Japan, the EU5, China and India. Smoking Cessation Drugs: World Market Prospects 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Smoking Cessation Drugs: World Market Prospects 2012-2022 please visit the website.

About Visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Smoking Cessation Drugs Market to Reach $2.4 Billion in 2012 Predicts Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today